Sparton — Q3 FY2014 Earnings Presentation
12 slides from Sparton's earnings presentation, May 7, 2014
Slide 1: Third Quarter Financial Results Conference Call
Exhibit 99.2 Third Quarter Financial Results Conference Call May 7, 2014
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements herein constitute forward-looking statements within the meaning of the Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended. When used herein, words such as “believe,” “expect,” “anticipate,” “project,” “plan,” “estimate,” “w
Slide 3: Today's Agenda
Today’s Agenda • 3rd Quarter Highlights • 3rd Quarter Segmented Operating Results • Liquidity & Capital Resources • Acquisition Update • Fiscal 2014 Outlook • Investor Activities • Q&A 3
Slide 4: 3rd Quarter Highlights
3rd Quarter Highlights • Quarterly revenue grew 29% to $84 million as compared to the same quarter of the prior year – Organic growth, net of acquisitions, was 11% from the same quarter of the prior year. • Adjusted EBITDA grew 120% in the quarter and 73% YTD as compared to the prior year periods •
Slide 5: Consolidated Financial Results
Consolidated Financial Results Fiscal 2014 YTD (Reported) (Adjusted) (Adjusted) 9 months ended Mar 31, 9 months ended Mar 31, Total YoY 2014 2013 2014 2013 Variance Net Sales $ 242,691 $ 183,203 $ 242,691 $ 183,203 $ 59,488 Gross Profit 43,597 30,220 43,853 30,786 13,067 18.0% 16.5% 18.1% 16.8% Sell
Slide 6: Consolidated Financial Results
Consolidated Financial Results Adjusted EBITDA 3 months ended Mar 31, 9 months ended Mar 31, 2014 2013 2014 2013 Variance Net Income $ 4,246 $ 1,536 $ 10,016 $ 7,834 $ 2,182 Interest expense 187 136 547 390 157 Interest income - (48) (2) (99) 97 Provision for income taxes 2,014 832 4,857 831 4,026 D
Slide 7: Operating Results
Operating Results Revenue & Gross Profit REVENUE 3 months ended Mar 31, 9 months ended Mar 31, SEGMENT 2014 % of Total 2013 % Change 2014 % of Total 2013 % Change Medical $ 37,215 44% $ 39,139 -5% $ 123,539 51% $ 102,002 21% Complex Systems 23,563 28% 16,482 43% 60,132 25% 42,888 40% DSS 28,853 34%
Slide 8: Liquidity & Capital Resources
Liquidity & Capital Resources 50,000 0.40 Cash Availability Net Debt-to-EBITDA ($ in '000) Mar-13 Jun-13 Sep-13 Dec-13 Mar-14 Leverage = 0.9x 0.35 0.34 Cash and equivalents 4,358 6,085 2,719 1,009 7,502 LOC Availability* 87,000 90,000 71,000 75,000 65,000 36,437 0.30 Total 91,358 96,085 73,719 76,00
Slide 9: Acquisition Update
Acquisition Update • Aubrey Group – Closed transaction on March 17, 2014 – Located in Irvine, CA – Design and contract manufacturing company using state-of-the-art technologies to develop new products for OEMs in the Medical and Biotechnological markets – Over 20 years of experience and expertise in
Slide 10: Fiscal 2014/2015 Outlook
Fiscal 2014/2015 Outlook • Implementation of the strategic growth plan – Continue to grow organically – Maintain our level of investment in internal research & development to commercially extend our product lines – Continue to enable our engineering workforce to develop new and innovative proprietar
Slide 11: Investor Activities
Investor Activities th • Sidoti Conference in NYC on May 9 th • B. Riley Investor Conference in Santa Monica on May 19 -21st nd • Barrington’s Spring Investor Day in Chicago on May 22 in Chicago th • KeyBanc Capital Markets Conference in Boston on May 27 -28 th th • East Coast Ideas Conference in Bo
Slide 12: Q&A
@) sparton Q&A 12